Commercialization of Ingredient Inspection Equipment, Organs on Chip, and Infection Prevention Solutions
First written in FY2021. 2 of 3 entries say "Advanced", first in FY2023. Latest entry: FY2024.
92 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「During fiscal 2023, the Company conducted efficacy verification tests against bacteria in actual hospitals, mainly in North America, in the infection-control field.」
The new business candidates progressed through efficacy verification of Care222 in hospitals in North America, demonstration testing of Clean172, and the successful development of Photobonding technology for Organs On Chip. - FY2023AdvancedAnnual report
「In addition to expanding the existing Environmental Hygiene Solutions and Healthcare businesses, the Company aims to create new businesses from a medium- to long-term perspective.」
In addition to expanding the environmental hygiene and healthcare fields, the Company progressed toward creating new businesses through investment in M&A to secure specialized personnel and acquire sales channels and peripheral technologies. - FY2021First statedAnnual report
「We are also narrowing the business focus to 3 areas: component inspection equipment, Organs on Chip, and infection prevention solutions. We are strengthening initiatives, including through active investment, with the goal of achieving profitability in several years.」
The Company narrowed its new business candidates to 3 areas and, for the first time, specifically presented a policy of strengthening proactive investment with the aim of achieving profitability in several years.